← Eichor
Condition: Efficacy Of Hemostatic Agents Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Efficacy Of Hemostatic Agents

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treatin
EARLY_Phase 1 · 1 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT07101705Talquetamab & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma
Phase 2 · 1 location(s) · Stanford University · NCT06461988Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab.
Phase 2 · 29 location(s) · European Myeloma Network B.V. · NCT07107529Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Thera
Phase 2 · 1 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT06140966A Study of BL-M24D1 in Patients With Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies
Phase 1 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT07255898A Study of TAK-330 to Reverse the Effects of Factor Xa Inhibitors For Adults Needing Urgent Surgery
Phase 3 · 64 location(s) · Takeda · NCT05156983AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
Phase 1/Phase 2 · 43 location(s) · AstraZeneca · NCT06106945Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-
Phase 1 · 8 location(s) · Newave Pharmaceutical Inc · NCT04771572Clinical Study on the Safety and Efficacy of BCMA-CART±ASCT in Treating Young Multiple Myeloma Patients
Phase 1/Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT07169500Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients
Phase 3 · 2 location(s) · Guangzhou Gloria Biosciences Co., Ltd. · NCT06514508A Study of ETHIZIA Versus SURGICEL Original in Controlling Soft Tissue Bleeding During Open Surgery
NA · 7 location(s) · Ethicon, Inc. · NCT06664788A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments
Phase 1/Phase 2 · 17 location(s) · Bristol-Myers Squibb · NCT05372354Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM)
Phase 1/Phase 2 · 2 location(s) · Starton Therapeutics, Inc · NCT06087653Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients
Phase N/A · 13 location(s) · Shanghai Zhongshan Hospital · NCT07663253A Phase I Study of SHR-3836 in Patients With Multiple Myeloma
Phase 1 · 1 location(s) · Shanghai Hengrui Pharmaceutical Co., Ltd. · NCT07490613A Study to Evaluate the Long-Term Safety of Idecabtagene Vicleucel Treatment in Adults With Newly Diagnosed Multiple Mye
Phase N/A · 5 location(s) · Bristol-Myers Squibb · NCT06698887Study of CT071 Injection in High Risk Newly Diagnosed Multiple Myeloma
EARLY_Phase 1 · 1 location(s) · Shanghai Changzheng Hospital · NCT06407947Safety and Efficacy of Metabolically Armed BCMA CAR-T Cells (Meta10-BCMA) in the Treatment of r/r Plasma Cell Neoplasms
EARLY_Phase 1 · 1 location(s) · Anhui Provincial Hospital · NCT07085559The Norwegian Immunotherapy in Multiple Myeloma Study
Phase N/A · 23 location(s) · St. Olavs Hospital · NCT06855121Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
Phase 1/Phase 2 · 24 location(s) · Heidelberg Pharma AG · NCT04879043To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma
Phase 1/Phase 2 · 4 location(s) · Hangzhou Sumgen Biotech Co., Ltd. · NCT07454187Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma
Phase 1/Phase 2 · 4 location(s) · Zhejiang ACEA Pharmaceutical Co. Ltd. · NCT05565807CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies
EARLY_Phase 1 · 1 location(s) · Zhejiang University · NCT04603872A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Ref
Phase 1 · 5 location(s) · Hoffmann-La Roche · NCT06934044A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple Myeloma
EARLY_Phase 1 · 5 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT07294625A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019A in Patients With Relapsed/Refractory Multipl
EARLY_Phase 1 · 1 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT07429721Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma
Phase 1 · 5 location(s) · Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · NCT07529782Safety and Efficacy of Fourth-Generation CAR-T in the Treatment of Hematologic Malignancies
Phase 1 · 1 location(s) · The Third Affiliated Hospital of Southern Medical University · NCT06758713Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries With Multiple Myeloma
Phase N/A · 1 location(s) · Center for International Blood and Marrow Transplant Researc · NCT03127761SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis
Phase 3 · 2 location(s) · Emory University · NCT04563520
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.